Acquisition and clearance of multidrug resistant Acinetobacter baumannii on healthy young adults concurrently burned in a dust explosion in Taiwan: the implication for antimicrobial stewardship

Table 1 Demographics and antimicrobial use of the healthy young adults admitted due to a dust explosion with or without MDRAB occurrence

	MDRAB (n = 9)	No MDRAB (n = 33)	P value
Age, median year (IQR)	19 (18–21)	21 (19–24)	0.275
Male, no. (%)	2 (22)	11 (49)	0.258
TBSA, %	50 (40–60)	45 (30–58)	0.460
APACHE II score (IQR)	6 (4–7)	6 (4–7)	0.409
Inhalation injury	2 (22)	14 (44)	0.442
Mechanical ventilation on admission, no. (%)	5 (56)	22 (67)	0.698
Mechanical ventilation at week 1, no. (%)	6 (67)	25 (76)	0.676
Mechanical ventilation at week 2, no. (%)	5 (56)	21 (64)	0.711
LOS before MDRAB occurrence, day (IQR)	16 (11–18)	NA	NA
Hospital day, median day (IQR)	93 (48–112)	53 (34–79)	0.018
Bacteremia, no. (%)	2 (22)	10 (24)	1.000
In-hospital mortality, no. (%)	0 (0)	2 (6%)	1.000
Antimicrobial exposure^a
Time-at-risk, patient-days^b	141	517
All antibiotics, DOT (DOT/1000 patient-days)	272 (1929)	977 (1890)	0.759
Carbapenem	92 (652)	199 (385)	< 0.001
Non-carbapenem Beta-lactam	42 (298)	276 (534)	< 0.001
Glycopeptide	116 (823)	384 (743)	0.335
Miscellaneous	22 (156)	118 (228)	0.093
Antifungal agent, DOT (DOT/1000 patient-days)	51 (361)	153 (296)	0.218
All antibiotics, DDD (DDD/1000 patient-days)	299 (2120)	1099 (2126)	0.975
Carbapenem	91 (642)	187 (362)	< 0.001
Non-carbapenem Beta-lactam	61 (431)	360 (695)	< 0.001
Glycopeptide	126 (893)	427 (826)	0.435
Miscellaneous	22 (153)	125 (243)	0.050
Antifungal agent, DDD (DDD/1000 patient-days)	81 (574)	276 (533)	0.557

Data are expressed as median and interquartile range or number (%) of patients unless otherwise indicated
^aAntimicrobial exposure is expressed as days of therapy (DOTs) and accumulated DOTs per 1000 patient-days
^bTime-at-risk for the controls was calculated as for the cases starting on the date of admission in a 1:3 or 1:4 case-control match. The time-at-risk of those controls were matched with that of the cases, if possible
APACHE Acute Physiology and Chronic Health Evaluation, DDD defined daily dose, DOT days of therapy, IQR interquartile range, LOS length of stay, MDRAB multidrug-resistant Acinetobacter baumannii, NA not applicable, TBSA total body surface area

ISSN: 1471-2334